News

CURE8d
Aidixi Plus Bacillus Calmette-Guérin Effective in Bladder Cancer
Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...
BioSpace10d
J&J Declares ‘Sustained Disease Control’ With Bladder Cancer Drug-Device Combo
The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...
New Breakthrough Cancer Test Could Double Survival Rate For Youngsters
A new trial in the United Kingdom has discovered a highly sensitive bone marrow test that could revolutionise the diagnosis ...
CURE10d
TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups
TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...
Yahoo Finance10d
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
The Phase 3 BOND-003 Cohort C study is in patients with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) treatment with carcinoma in situ (CIS ...
Morningstar7d
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
They include: Saum Ghodoussipour, M.D., Rutgers Cancer Institute of New Jersey: Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer Taylor Goodstein, M.D., Emory University ...